? PROJECT 2 There are 2.5 million severe asthma patients in US. These patients are typically unresponsive, or poorly responsive to currently available asthma drugs. Therefore there is high unmet medical need for these patients. Several studies have suggested a central role for IL-17 (also called IL-17A) in severe asthma. Project 2's studies in the Program during Cycle I revealed the importance of IL-17 signaling pathways in the pathogenesis of asthma. The overall goal of Cycle II will focus on developing new therapeutic agents to block IL-17A pathway for the treatment of severe asthma. Project 2 was selected in 2015 to receive NCAI-CC support to begin to advance discoveries into novel therapies for severe asthma. Using IL-17R-deficient mice, Project 2 demonstrated the critical role of IL-17A signaling in High-Fat Diet-induced airway hyperreactivity and Aspergillus-induced animal model of severe asthma. Thus, Project 2 hypothesizes that the IL-17A pathway is an important target for the treatment of severe and steroid-resistant asthma. Through computer-aided virtual screening based on the crystal structure of IL-17RA/IL-17A complex, Project 2 has identified one small molecule lead compound (A18) that inhibits IL-17A binding to IL-17RA in in vitro biochemical assay, in IL-17A- induced gene expression in cultured cells and in preclinical studies, i.e. attenuation of IL-17A-dependent neutrophilia, airway inflammation, and airway hyper-reactivity. Project 2 has also developed a decoy peptide of Act1 (adaptor for IL-17R) to inhibit IL-17A intracellular signaling, and IL17A biomarkers that will facilitate the identification of patient populations responsive to IL-17A inhibitors. Project 2 aims to (1) further optimize the A18 structure for better bioactivities with drug-like properties for a 2nd generation of lead compound(s) and develop peptidomimetics based on the decoy peptides; (2) validate A18, A18 derivatives and peptidomimetics in IL-17A-induced pulmonary neutrophilia, HFD- and Aspergillus-induced severe asthma models in collaboration with Aronica's lab and the Animal Core (Dr. Asosingh); (3) partnering with Novartis, Project 2 will collaborate with Project 1 on defining the Biomarkers for IL-17A-targeted treatment. Additionally, Project 2 will interact with the regulatory experts through Core B for pre-IND advice from the FDA in order to submit the required data for an IND application to move the small molecule development candidate into the clinic. As part of the commercialization plan, Project 2 is enthusiastic to explore the possibility of developing the platform of small molecule and peptidomimetic strategy through the creation of a start-up in Cleveland. Core B will work with Project 2 to identify team members for the start-up with prior life sciences technology start-up experience in order to, raise capital to invest in de-risking the technology to make it more attractive for joint development with a pharma partner or to position the start-up as a competitive acquisition target.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL103453-06
Application #
9146559
Study Section
Special Emphasis Panel (ZHL1-PPG-S (M1))
Program Officer
Noel, Patricia
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
6
Fiscal Year
2016
Total Cost
$788,528
Indirect Cost
$276,302
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Ghosh, Arnab; Stuehr, Dennis J (2017) Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives. Antioxid Redox Signal 26:182-190
Israel, Laura; Wang, Ying; Bulek, Katarzyna et al. (2017) Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity. Cell 168:789-800.e10
Zepp, Jarod A; Zhao, Junjie; Liu, Caini et al. (2017) IL-17A-Induced PLET1 Expression Contributes to Tissue Repair and Colon Tumorigenesis. J Immunol 199:3849-3857
Modena, Brian D; Bleecker, Eugene R; Busse, William W et al. (2017) Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. Am J Respir Crit Care Med 195:1449-1463
Chen, Jiwang; Sysol, Justin R; Singla, Sunit et al. (2017) Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension. Circulation 135:1532-1546
Stober, Vandy P; Johnson, Collin G; Majors, Alana et al. (2017) TNF-stimulated gene 6 promotes formation of hyaluronan-inter-?-inhibitor heavy chain complexes necessary for ozone-induced airway hyperresponsiveness. J Biol Chem 292:20845-20858
Gu, Xiaodong; Huang, Ying; Levison, Bruce S et al. (2016) Identification of Critical Paraoxonase 1 Residues Involved in High Density Lipoprotein Interaction. J Biol Chem 291:1890-904
Martin, Bradley N; Wang, Chenhui; Zhang, Cun-jin et al. (2016) T cell-intrinsic ASC critically promotes T(H)17-mediated experimental autoimmune encephalomyelitis. Nat Immunol 17:583-92
Reeves, Stephen R; Kaber, Gernot; Sheih, Alyssa et al. (2016) Subepithelial Accumulation of Versican in a Cockroach Antigen-Induced Murine Model of Allergic Asthma. J Histochem Cytochem 64:364-80
Cheong, Hoi I; Asosingh, Kewal; Stephens, Olivia R et al. (2016) Hypoxia sensing through ?-adrenergic receptors. JCI Insight 1:e90240

Showing the most recent 10 out of 121 publications